Halozyme Therapeutics Inc. (NASDAQ: HALO) is 60.98% higher on its value in year-to-date trading and has touched a low of $32.83 and a high of $65.53 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HALO stock was last observed hovering at around $62.31 in the last trading session, with the day’s loss setting it -2.81%.
Currently trading at $59.50, the stock is -3.67% and 2.72% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.72 million and changing -4.51% at the moment leaves the stock 31.69% off its SMA200. HALO registered 49.61% gain for a year compared to 6-month gain of 47.35%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.35% loss in the last 1 month and extending the period to 3 months gives it a 16.99%, and is -1.72% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.55% over the week and 2.97% over the month.
Halozyme Therapeutics Inc. (HALO) has around 373 employees, a market worth around $7.54B and $873.30M in sales. Current P/E ratio is 23.07 and Fwd P/E is 12.53. Profit margin for the company is 38.62%. Distance from 52-week low is 81.24% and -9.21% from its 52-week high. The company has generated returns on investments over the last 12 months (18.82%).
with sales reaching $255.92M over the same period.The EPS is expected to grow by 43.64% this year, but quarterly earnings will post 18.50% year-over-year. Quarterly sales are estimated to grow 18.50% in year-over-year returns.
628.0 institutions hold shares in Halozyme Therapeutics Inc. (HALO), with institutional investors hold 99.50% of the company’s shares. The shares outstanding are 126.77M, and float is at 125.30M with Short Float at 8.01%. Institutions hold 98.42% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 17.62 million shares valued at $922.58 million. The investor’s holdings represent 13.8804 of the HALO Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.88 million shares valued at $674.47 million to account for 10.1476 of the shares outstanding. The other top investors are STATE STREET CORP which holds 5.81 million shares representing 4.5802 and valued at over $304.43 million, while SNYDER CAPITAL MANAGEMENT L P holds 3.1825 of the shares totaling 4.04 million with a market value of $211.53 million.
Halozyme Therapeutics Inc. (HALO) Insider Activity
The most recent transaction is an insider sale by LaBarre Michael J., the company’s SVP, CHIEF TECHNICAL OFFICER. SEC filings show that LaBarre Michael J. sold 10,000 shares of the company’s common stock on Sep 17 ’24 at a price of $62.88 per share for a total of $0.63 million. Following the sale, the insider now owns 0.17 million shares.
Halozyme Therapeutics Inc. disclosed in a document filed with the SEC on Sep 18 ’24 that LaBarre Michael J. (SVP, CHIEF TECHNICAL OFFICER) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Sep 18 ’24 and was made at $62.03 per share for $0.62 million. Following the transaction, the insider now directly holds 0.17 million shares of the HALO stock.
Still, SEC filings show that on Sep 18 ’24, MICHAEL LABARRE (Officer) Proposed Sale 10,000 shares at an average price of $62.03 for $0.62 million. The insider now directly holds shares of Halozyme Therapeutics Inc. (HALO).
